about
Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance PredictionTherapeutic suppression of premature termination codons: mechanisms and clinical considerations (review)Study of streptomycin-induced ototoxicity: protocol for a longitudinal study.Gentamicin Binds to the Megalin Receptor as a Competitive Inhibitor Using the Common Ligand Binding Motif of Complement Type Repeats: INSIGHT FROM THE NMR STRUCTURE OF THE 10TH COMPLEMENT TYPE REPEAT DOMAIN ALONE AND IN COMPLEX WITH GENTAMICINRevealing the dynamics of polymicrobial infections: implications for antibiotic therapy.Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Population pharmacokinetics of gentamicin and dosing optimization for infantsSimplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patientsAminoglycoside resistance in Pseudomonas aeruginosa.Pharmacokinetics of intraperitoneal gentamicin in peritoneal dialysis patients with peritonitis (GIPD study).Pharmacokinetic modeling of gentamicin in treatment of infective endocarditis: Model development and validation of existing models.Development of generic immunoassay for the detection of a series of aminoglycosides with 6'-OH group for the treatment of genetic diseases in biological samples.Pharmacokinetics and pharmacodynamics of antibacterial agents.Hydrophobic gentamicin-loaded nanoparticles are effective against Brucella melitensis infection in mice.Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and InfantsMedication-related complications in the trauma patient.Gentamicin-mediated ototoxicity and nephrotoxicity: A clinical trial study.Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy.Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity.Antibiotic dosing in critically ill patients with acute kidney injury.Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients.Inhaled antibiotics for gram-negative respiratory infections.Aminoglycoside-induced nephrotoxicity.Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy.Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.No increased risk of acute kidney injury after a single dose of gentamicin in patients with sepsis.Extended-interval gentamicin administration in neonates: a simplified approach.Interactions among osteoblastic cells, Staphylococcus aureus, and chitosan-immobilized titanium implants in a postoperative coculture system: An in vitro study.Once-daily gentamicin administration for community-associated methicillin resistant Staphylococcus aureus in an in vitro pharmacodynamic model: preliminary reports for the advantages for optimizing pharmacodynamic index.Optimal aminoglycoside therapy following the sepsis: how much is too much?Finding ways to solve or prevent aminoglycoside-induced ototoxicity?Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa.Multi-residue quantitation of aminoglycoside antibiotics in kidney and meat by liquid chromatography with tandem mass spectrometry.Vestibulotoxicity with systemic gentamicin in different dosing regimens: Our experience in 46 patients.Aminoglycoside resistance mechanisms in Pseudomonas aeruginosa isolates from non-cystic fibrosis patients in Thailand.Systemic exposure to tobramycin after local antibiotic treatment with calcium sulphate as carrier material.Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
P2860
Q26753831-3FA3F191-CE53-4DE3-BB86-511C54FF2DCAQ26853614-92306653-EB8D-41E6-B596-40A6687F9EFBQ27318765-E4396BBD-925E-40CF-B225-7C3B6C9761FCQ27675654-6D51279F-ECC4-44C8-9DEB-822B0FA9B473Q34554419-3AC9182D-13BA-4DDF-9495-83FFF95498EEQ34570930-49987A92-9FCB-48C0-969E-B4160743DF1BQ34894900-0C45AD30-288E-442A-9A6A-B29DF7CB20AFQ34923469-253E3283-7B32-4DDA-A9BF-7BAA3C4A9E41Q35191383-F7D17B73-9F31-424E-A514-F4052F6BD3A2Q36021296-A4421937-1353-446B-B934-D9DD35446B0CQ36126934-B005FFB7-06FD-48F8-B68C-5E5BB26CC8C3Q36364337-A0D157F2-FB67-4B3C-A885-0D235461C5CCQ36533566-E1C9EEE2-6B37-4852-AE86-94335771D40BQ36911111-5DEF63AD-12BA-421F-81D7-B8616CBC0B79Q36969831-971AF7BC-1334-4CAB-AF31-490D78B87F7FQ37120041-D9678E33-990E-4E0F-931C-4990E28AF2E7Q37121344-C1DFD937-AB1F-4F0B-8B8F-DD50ACBE9EABQ37449590-E1DB4406-FFEE-4767-AEB5-2E7F46005BC3Q37661501-AEAC5F29-3BCB-4781-A336-C6DC45FB0D72Q37839231-0D94F6DA-1A11-446C-A619-02BE781D40D4Q37846092-0E1E0448-695F-4244-8824-EA00791C2CC2Q37867260-A919622E-78DE-4C1A-B083-48A359AA7D8CQ37937558-FF187EBB-30FC-4213-B874-AC7B25DF2C90Q38246945-69F8AD06-1C18-471B-949B-87CDF08F9660Q38626980-0735BC2D-C291-44F2-8C81-FEFEE066F4CEQ39071799-06FE7F37-754B-4C52-AD36-2F2EC6A1B89EQ39097052-BCE7E46A-EA1D-45A4-9C89-C1896118C9A2Q40265579-15CF6A83-4C6F-4167-AD65-DCDBDF69DD35Q40322197-51A4AAAD-C92F-4B1F-885D-651C3BFA2401Q40751575-AE6B426D-86D3-4540-A07B-70CCA4F6D56EQ40942718-E8D334F4-4487-45B0-AF15-226612E4F298Q41877860-FC43FB5A-2A1A-4E96-B2CA-52E698BF2DA0Q41963116-2B47A1A0-B81A-47FF-BE71-D13671131154Q42330819-52A6B4E5-DA39-4CEE-B522-76F8B4E22375Q42549535-1EA57F6A-A92F-4329-B087-5B4C92DEA714Q43292113-65B64A8D-61BE-4A1B-831F-9C85AFF52D14Q44183930-5393B935-E81D-4D0D-8D18-0F9452CA93A2Q44734485-FEBF591C-FDD7-48AC-8CC1-562757B21CB7Q45070708-52798354-8A07-4E3F-A66F-E569D2D213D1Q45978260-7DA01306-ECD0-41F3-8FF5-E22E0AFCBE3F
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Pharmacodynamics and dosing of aminoglycosides.
@ast
Pharmacodynamics and dosing of aminoglycosides.
@en
type
label
Pharmacodynamics and dosing of aminoglycosides.
@ast
Pharmacodynamics and dosing of aminoglycosides.
@en
prefLabel
Pharmacodynamics and dosing of aminoglycosides.
@ast
Pharmacodynamics and dosing of aminoglycosides.
@en
P1476
Pharmacodynamics and dosing of aminoglycosides.
@en
P2093
John Turnidge
P304
P356
10.1016/S0891-5520(03)00057-6
P577
2003-09-01T00:00:00Z